RT Journal Article
SR Electronic
T1 Assessing clinical acuity in the Emergency Department using the GPT-3.5 Artificial Intelligence Model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.09.23293795
DO 10.1101/2023.08.09.23293795
A1 Williams, Christopher Y.K.
A1 Zack, Travis
A1 Miao, Brenda Y.
A1 Sushil, Madhumita
A1 Wang, Michelle
A1 Butte, Atul J.
YR 2023
UL http://medrxiv.org/content/early/2023/08/13/2023.08.09.23293795.abstract
AB This paper evaluates the performance of the Chat Generative Pre-trained Transformer (ChatGPT; GPT-3.5) in accurately identifying higher acuity patients in a real-world clinical context. Using a dataset of 10,000 pairs of patient Emergency Department (ED) visits with varying acuity levels, we demonstrate that GPT-3.5 can successfully determine the patient with higher acuity based on clinical history sections extracted from ED physician notes. The model achieves an accuracy of 84% and an F1 score of 0.83, with improved performance for more disparate acuity scores. Among the 500 pair subsample that was also manually classified by a resident physician, GPT-3.5 achieved similar performance (Accuracy = 0.84; F1 score = 0.85) compared to the physician (Accuracy = 0.86, F1 score = 0.87). Our results suggest that, in real-world settings, GPT-3.5 can perform comparably to physicians on the clinical reasoning task of ED acuity determination.Competing Interest StatementAJB is a co-founder and consultant to Personalis and NuMedii; consultant to Mango Tree Corporation, and in the recent past, Samsung, 10x Genomics, Helix, Pathway Genomics, and Verinata (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute, Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, and Merck, and Roche; is a shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Meta (Facebook), Alphabet (Google), Microsoft, Amazon, Snap, 10x Genomics, Illumina, Regeneron, Sanofi, Pfizer, Royalty Pharma, Moderna, Sutro, Doximity, BioNtech, Invitae, Pacific Biosciences, Editas Medicine, Nuna Health, Assay Depot, and Vet24seven, and several other non-health related companies and mutual funds; and has received honoraria and travel reimbursement for invited talks from Johnson and Johnson, Roche, Genentech, Pfizer, Merck, Lilly, Takeda, Varian, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Westat, and many academic institutions, medical or disease specific foundations and associations, and health systems. AJB receives royalty payments through Stanford University, for several patents and other disclosures licensed to NuMedii and Personalis. AJB's research has been funded by NIH, Peraton (as the prime on an NIH contract), Genentech, Johnson and Johnson, FDA, Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation, Priscilla Chan and Mark Zuckerberg, the Barbara and Gerson Bakar Foundation, and in the recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California Governor's Office of Planning and Research, California Institute for Regenerative Medicine, L'Oreal, and Progenity. None of these entities had any bearing on the design of this study or the writing of the manuscript.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UCSF Institutional Review Board determined that this use of deidentified structured and clinical text data in the UCSF Information Commons is considered non-human-participants research and was exempt from further approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData available: No